Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

NCT ID: NCT05284799

Last Updated: 2024-10-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-09
• Study Completion Date: 2022-12-09

Brief Summary

The present study will evaluate the concomitant administration of a Quadrivalent Inactivated Influenza Vaccine with the highest dose level of OVX836 (480µg) tested in the clinic to date, for which the likelihood for interference with Quadrivalent Inactivated Influenza Vaccine is considered the highest.

Detailed Description

This trial is a Phase 2a, randomized, double-blind, controlled study in 180 adult subjects to compare the immunogenicity and the safety of the concomitant administration (given intramuscularly, in healthy subjects, as 2 separate injections in the same arm) of:

• OVX836 influenza vaccine and a Quadrivalent Inactivated Influenza Vaccine
• Quadrivalent Inactivated Influenza Vaccine and placebo
• OVX836 influenza vaccine and placebo

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

OVX836 480µg + Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose

OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1

AND

Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine.

Group Type: EXPERIMENTAL

OVX836 480µg

Intervention Type: BIOLOGICAL

One single administration intramuscularly at Day 1

Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)

Intervention Type: BIOLOGICAL

One single administration intramuscularly at Day 1

Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra) at commercial dose + Placebo

Fluarix® Tetra (GlaxoSmithKline Biologicals): Inactivated and purified split influenza vaccine.

AND

Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1

Group Type: ACTIVE_COMPARATOR

Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)

Intervention Type: BIOLOGICAL

One single administration intramuscularly at Day 1

Placebo

Intervention Type: BIOLOGICAL

One single administration intramuscularly at Day 1

OVX836 480µg + Placebo

OVX836: Adjuvant-free recombinant influenza candidate vaccine based on Nucleoprotein of the incluenza virus. One single administration intramuscularly of 480µg dose on Day 1

AND

Placebo Comparator: Saline solution (B. Braun Ecoflac Plus) Saline solution (NaCl 0,9%), B. Braun Ecoflac Plus 50mL. One single administration intrumuscularly of a 0.8mL dose on Day 1

Group Type: PLACEBO_COMPARATOR

OVX836 480µg

Intervention Type: BIOLOGICAL

One single administration intramuscularly at Day 1

Placebo

Intervention Type: BIOLOGICAL

One single administration intramuscularly at Day 1

Interventions

OVX836 480µg

One single administration intramuscularly at Day 1

Intervention Type: BIOLOGICAL

Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)

One single administration intramuscularly at Day 1

Intervention Type: BIOLOGICAL

Placebo

One single administration intramuscularly at Day 1

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Written informed consent.

2. Healthy male or female subjects, as determined by medical history and medical examination.

3. Between the age of 18 and 55 years, inclusive.

4. Subjects who have fully been vaccinated with licensed Severe Acute Respiratory Syndrome Coronavirus-2 (COVID-19) vaccine(s) according to national recommendations for the corresponding population group, in vigor at the moment the study starts.

5. Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures.

6. Ability and technical possibility for completing an e-diary and ePRO.

Exclusion Criteria

1. Subjects with a body mass index ≤19 kg/m² or ≥35 kg/m² on the day of vaccination.

2. Previous influenza vaccination within 6 months before the day of vaccination or planned to receive during the study duration.

3. Any known or suspected immunodeficient conditions.

4. Past or current history of significant autoimmune diseases, as judged by the Investigator.

5. Current history of uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases.

6. Known or suspected infection with human immunodeficiency virus, hepatitis C virus, or hepatitis B virus, based upon medical history or physical examination findings.

7. Female subjects: pregnant, breast-feeding or of childbearing potential without appropriate contraceptive methods in place for 2 months before enrolment, or with positive pregnancy test on the day of vaccination. Appropriate contraceptive methods are to be maintained until the end of the trial. Appropriate contraceptive methods are defined by the Clinical Trial Facilitation Group as follow: "Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable intrauterine device, intrauterine hormone-releasing system), bilateral tubal occlusion, vasectomized partner and/or sexual abstinence (refraining from heterosexual intercourse)."

8. Having received another vaccination within 3 months prior to the day of study vaccination with live attenuated vaccines, or within 1 month prior to the day of study vaccination with inactivated vaccines, except COVID-19 vaccine.

9. Planning to receive other vaccines during the first 28 days following the study vaccine administration, except COVID-19 vaccine.

10. Having received a COVID-19 vaccination within 2 weeks prior to the day of study vaccination.

11. Planning to receive COVID-19 vaccine during the first week (within 7 days) following the study vaccine administration. An interval of preferably 14 days is recommended. If for scheduling reasons, COVID-19 vaccine has to be given on Day 8, the vaccination should be administered after completion of the study procedures.

12. Administration of any investigational or non-registered drug or vaccine within 3 months prior to the administration of study vaccines, or planned administration of any such product during the whole study period.

13. History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination, or planned to receive such product during the whole study period.

14. Presence of an acute febrile illness on the day of vaccination (oral temperature >38.0°C, temporary exclusion criterion).

15. Past or current history of any progressive or severe neurological disorder, seizure disorder or Guillain-Barré syndrome.

16. Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study.

17. Past (stopped less than 6 months before enrolment) or current history of alcohol or drug abuse, or current smoking habit above 10 cigarettes per day, or current vaping.

18. Treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (>800μg/day beclomethasone or equivalent; occasional inhaled corticosteroids for asthma therapy are allowed), radiation treatment, cytotoxic drugs, or current or recent (within 30 days before study entry) chronic or prolonged (>10 days) use of systemic non-steroidal anti-inflammatory drugs, interferon, immunomodulators, allergy shots, as judged by the Investigator.

19. History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions to vaccines or allergy to any component of either of the study vaccines, including to egg protein or to kanamycin.

20. Any contraindication to IM administration, as judged by the Investigator, including bleeding disorders such as hemophilia or anticoagulant therapy.

21. Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

22. Subjects with tattoos in the deltoid region bilaterally, which might interfere with observation of local signs and symptoms or other adverse events at the injection sites. In case of tattoos on one side, injections of study vaccines should be performed in the contralateral arm.

23. Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted, including children of newly composed families.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Northern Beaches Clinical Research

UNKNOWN

Sponsor Role: collaborator

Novotech (Australia) Pty Limited

INDUSTRY

Sponsor Role: collaborator

Harmony Clinical Research BVBA

OTHER

Sponsor Role: collaborator

Osivax

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ross Aldrich, MBBS

Role: PRINCIPAL_INVESTIGATOR

Northern Beaches Clinical Research

Locations

Northern Beaches Clinical Research

Brookvale, New South Wales, Australia

Countries

Australia

References

Groth N, Bruhwyler J, Tourneur J, Piat E, Moris P, Le Vert A, Nicolas F. Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with Fluarix(R) Tetra, a Seasonal Hemagglutinin-Based Vaccine. Vaccines (Basel). 2025 May 23;13(6):558. doi: 10.3390/vaccines13060558.

Reference Type: DERIVED

PMID: 40573889 (View on PubMed)

Other Identifiers

OVX836-004

Identifier Type: -

Identifier Source: org_study_id